| Balance Sheets | 2026-03-31 | 2025-12-31 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 4,219,099 | 1,025,987 | ||
| Accounts receivable, net | 201,481 | 199,954 | ||
| Inventory | 104,523 | 116,217 | ||
| Prepaid expenses and other current assets | 175,174 | 128,975 | ||
| Total current assets | 4,700,277 | 1,471,133 | ||
| License agreement, net | 265,518 | 271,143 | ||
| Total property and equipment | 540,452 | NaN | ||
| Less accumulated depreciation | 495,265 | NaN | ||
| Property and equipment, net | 45,187 | 56,677 | ||
| Intangible assets, gross | NaN | 243,644 | ||
| Less accumulated amortization | NaN | 41,380 | ||
| Intangible asset, net | 206,801 | 202,264 | ||
| Right-of-use assets, net | 562,507 | 605,289 | ||
| Deferred offering costs | NaN | 1,507,794 | ||
| Other assets | 23,057 | 23,057 | ||
| Total assets | 5,803,347 | 4,137,357 | ||
| Accounts payable | 980,486 | 868,545 | ||
| Accrued liabilities | 598,335 | 785,784 | ||
| Accrued dividends series e convertible preferred stock | 54,192 | NaN | ||
| Convertible note | 306,716 | 74,611 | ||
| Deferred revenue | 450,667 | 414,871 | ||
| Operating lease liability current | 189,649 | 175,948 | ||
| Accrued dividends series e convertible preferred stock | 54,192 | NaN | ||
| Derivative liability current | 0 | 143,382 | ||
| Total current liabilities | 2,580,045 | 2,463,141 | ||
| Deferred revenue long-term | 37,055 | 41,816 | ||
| Operating lease liability long term | 429,122 | 488,725 | ||
| Convertible notes payable, net | 0 | 619,355 | ||
| Derivative liabilities long-term | 0 | 543,545 | ||
| Total long-term liabilities | 466,177 | 1,693,441 | ||
| Total liabilities | 3,046,222 | 4,156,582 | ||
| Series e convertible preferred stock, 0.01 par value 45,000 authorized 5,000 and 0 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively liquidation preference of 5,494,500 | 204,239 | NaN | ||
| Common stock, 0.01 par value 50,000,000 authorized 10,442,960 and 5,442,249 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 104,430 | 54,422 | ||
| Additional paid-in capital | 37,870,511 | 33,126,398 | ||
| Accumulated deficit | -35,422,055 | -33,247,219 | ||
| Preferred stock value-Series DPreferred Stock | 0 | 1,016 | ||
| Preferred stock value-Series CPreferred Stock | 0 | 12,040 | ||
| Preferred stock value-Series BPreferred Stock | 0 | 14,715 | ||
| Preferred stock value-Series A2Preferred Stock | 0 | 4,424 | ||
| Preferred stock value-Series A1Preferred Stock | 0 | 6,515 | ||
| Preferred stock value-Series APreferred Stock | 0 | 8,464 | ||
| Total stockholders (deficit) equity | 2,552,886 | -19,225 | ||
| Total liabilities, contingently redeemable preferred stock and stockholders equity | 5,803,347 | 4,137,357 | ||
20 20 Biolabs, Inc. (AIDX)
20 20 Biolabs, Inc. (AIDX)